COL3A1 : Potential prognostic predictor for head and neck cancer based on immune‐microenvironment alternative splicing
Cancer Medicine · 2023-02 · 12 (4) · 4882-4894
DOI: 10.1002/cam4.5170 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 29.08.2022. Verfasst von Yuchen Shen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Vascular Anomaly Center, Department of Interventional Therapy, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Sh…. Hauptthemen laut MEDLINE: Alternative Splicing, Head and Neck Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Postdoctoral Science Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
We aimed to identify a novel prognostic biomarker for head and neck squamous cell carcinoma (HNSCC) based on tumor immunology‐related alternative splicing (AS). Data for 502 HNSCC and 44 normal samples were obtained from the TCGA database and used to establish an AS‐related risk model through univariate, least absolute shrinkage, and selection operator Cox regression analyses. Fresh HNSCC and normal oral tissues were surgically obtained from 44 HNSCC patients. Western blotting and quantitative reverse transcription‐PCR were used to assess gene expression levels. Kaplan–Meier was performed to evaluate patients' overall survival (OS) rate. The CIBERSORT algorithm, single‐sample gene set enrichment analysis, and immune checkpoint analyses were performed to compare immune activities between subgroups. The risk model was established using 10 pivotal AS events first. Collagen Type III Alpha 1 Chain ( COL3A1 ) were screened based on |log2FC| ≥ 1 and FDR < 0.05 criteria. COL3A1 expression levels in HNSCC tissues were elevated relative to normal tissues ( p < 0.001). Moreover, COL3A1 was a reliable biomarker for HNSCC patients' prognostic prediction in both cohorts ( p < 0.001, p = 0.0085, respectively). COL3A1 protein ( p = 0.0054) and mRNA ( p < 0.0001) levels were correlated with HNSCC differentiation. Furthermore, the T stage was correlated with COL3A1 expression ( p = 0.043), and COL3A1 expression was an independent prognostic predictor for HNSCC patients ( p = 0.006). Compared with the risk model, COL3A1 was better at evaluating immune cell infiltrations, immune activities, and immune checkpoint gene expressions of HNSCC lesions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vascular Anomaly Center, Department of Interventional Therapy, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology, National Clinical Research Centre for Oral Diseases, Shanghai, China.
- Department of Neurosurgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
ORCID-Profile: Yuchen Shen, Xitao Yang
Förderung
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
Zitieren
APA
Shen, Y., Li, X., Wang, D., Zhang, L., Li, X., Su, L., Fan, X., & Yang, X. (2023). COL3A1 : Potential prognostic predictor for head and neck cancer based on immune‐microenvironment alternative splicing. Cancer Medicine, 12(4), 4882-4894. https://doi.org/10.1002/cam4.5170
Vancouver
Shen Y, Li X, Wang D, Zhang L, Li X, Su L, et al. COL3A1 : Potential prognostic predictor for head and neck cancer based on immune‐microenvironment alternative splicing. Cancer Medicine. 2023;12(4):4882-4894. doi:10.1002/cam4.5170
BibTeX
@article{Shen2023,
author = {Shen, Yuchen and Li, Xinyu and Wang, Deming and Zhang, Liming and Li, Xiao and Su, Lixin and Fan, Xindong and Yang, Xitao},
title = {COL3A1 : Potential prognostic predictor for head and neck cancer based on immune‐microenvironment alternative splicing},
journal = {Cancer Medicine},
year = {2023},
volume = {12},
number = {4},
pages = {4882--4894},
doi = {10.1002/cam4.5170}
}
EUVIMED